Biotheus Inc.
Clinical trials sponsored by Biotheus Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers Results expected Jan 2027 (estimated)
- New hope for tough lung cancer: Dual-Action drug combo in final testing Results expected Jan 2027 (estimated)
- Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer? Results expected May 2027 (estimated)
- Can an immunotherapy drug boost chemotherapy's power against a tough breast cancer? Results expected Jul 2027 (estimated)